alvocidib

Flavopiridol (Alvocidib) 是一种广谱CDK 竞争型抑制剂， 抑制 CDK1，CDK2，CDK4的IC50分别为30，170，100 nM。

Flavopiridol hydrochloride (MDL 107826A) 是一种CDK 的广谱抑制剂，与 ATP 竞争性地抑制 CDK1，CDK2 和 CDK4 的活性，IC50值分别为 30, 170, 100 nM。

Zotiraciclib（又名TG02和SB1317）是一种新型小分子化合物，具有强效的CDK JAK2 FLT3抑制作用。该化合物可通过抑制周期蛋白依赖性激酶9（CDK9），耗竭Myc来治疗能穿越血脑屏障的癌症。Zotiraciclib是正在研究的众多CDK抑制剂之一，其他针对CDK9的化合物，用于治疗急性髓细胞性白血病的还包括alvocidib和atuveciclib。许多癌症中的Myc过表达是一个已知因素，其中80%的胶质母细胞性瘤展现此特性。

Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK JAK2 FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.